Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary

1 Nov 2021

Abstract excerpt

PURPOSE Cancer of unknown primary (CUP) is a metastatic disease with unidentifiable primary tumor. Somatic alterations can be assessed noninvasively via liquid biopsies interrogating cell-free DNA (cfDNA). METHODS We evaluated 1,931 patients with CUP with a cfDNA next-generation sequencing panel (73-74 genes). RESULTS Overall, 1,739 patients (90%) had ≥ 1 cfDNA alteration. We then explored alteration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Diagnosis and Treatment
Share to Cancer Genomics and Diagnostics
Share to Tumors and Oncological Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34778692
DOI: 10.1200/po.21.00011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryPMID 34778692Read ↗

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimarySemantic proximity Read ↗

Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown PrimarySemantic proximity Read ↗

Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.Semantic proximity Read ↗

A prospective national precision medicine trial comparing blood and tissue profiling in patients with Cancer of Unknown Primary (CUPCOMP)Semantic proximity Read ↗

Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primarySemantic proximity Read ↗

Significance of distinct liquid biopsy compartments in evaluating somatic mutations for targeted therapy selection in cancer of unknown primarySemantic proximity Read ↗

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknownSemantic proximity Read ↗

A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primarySemantic proximity Read ↗

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity Read ↗

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.Semantic proximity Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.